221 related articles for article (PubMed ID: 10399097)
1. Ceramide accumulation is associated with increased apoptotic cell death in cultured fibroblasts of sphingolipid activator protein-deficient mouse but not in fibroblasts of patients with Farber disease.
Tohyama J; Oya Y; Ezoe T; Vanier MT; Nakayasu H; Fujita N; Suzuki K
J Inherit Metab Dis; 1999 Jun; 22(5):649-62. PubMed ID: 10399097
[TBL] [Abstract][Full Text] [Related]
2. Model SV40-transformed fibroblast lines for metabolic studies of human prosaposin and acid ceramidase deficiencies.
Chatelut M; Harzer K; Christomanou H; Feunteun J; Pieraggi MT; Paton BC; Kishimoto Y; O'Brien JS; Basile JP; Thiers JC; Salvayre R; Levade T
Clin Chim Acta; 1997 Jun; 262(1-2):61-76. PubMed ID: 9204210
[TBL] [Abstract][Full Text] [Related]
3. Sulfatide and sphingomyelin loading of living cells as tools for the study of ceramide turnover by lysosomal ceramidase--implications for the diagnosis of Farber disease.
Levade T; Tempesta MC; Moser HW; Fensom AH; Harzer K; Moser AB; Salvayre R
Biochem Mol Med; 1995 Apr; 54(2):117-25. PubMed ID: 8581356
[TBL] [Abstract][Full Text] [Related]
4. Interfacial regulation of acid ceramidase activity. Stimulation of ceramide degradation by lysosomal lipids and sphingolipid activator proteins.
Linke T; Wilkening G; Sadeghlar F; Mozcall H; Bernardo K; Schuchman E; Sandhoff K
J Biol Chem; 2001 Feb; 276(8):5760-8. PubMed ID: 11104761
[TBL] [Abstract][Full Text] [Related]
5. Neurodegenerative course in ceramidase deficiency (Farber disease) correlates with the residual lysosomal ceramide turnover in cultured living patient cells.
Levade T; Moser HW; Fensom AH; Harzer K; Moser AB; Salvayre R
J Neurol Sci; 1995 Dec; 134(1-2):108-14. PubMed ID: 8747852
[TBL] [Abstract][Full Text] [Related]
6. Substrate-specificities of acid and alkaline ceramidases in fibroblasts from patients with Farber disease and controls.
Momoi T; Ben-Yoseph Y; Nadler HL
Biochem J; 1982 Aug; 205(2):419-25. PubMed ID: 6814427
[TBL] [Abstract][Full Text] [Related]
7. Turnover of endogenous ceramide in cultured normal and Farber fibroblasts.
van Echten-Deckert G; Klein A; Linke T; Heinemann T; Weisgerber J; Sandhoff K
J Lipid Res; 1997 Dec; 38(12):2569-79. PubMed ID: 9458280
[TBL] [Abstract][Full Text] [Related]
8. A simple method for screening for Farber disease on cultured skin fibroblasts.
Chatelut M; Feunteun J; Harzer K; Fensom AH; Basile JP; Salvayre R; Levade T
Clin Chim Acta; 1996 Feb; 245(1):61-71. PubMed ID: 8646815
[TBL] [Abstract][Full Text] [Related]
9. Stimulation of acid ceramidase activity by saposin D.
Azuma N; O'Brien JS; Moser HW; Kishimoto Y
Arch Biochem Biophys; 1994 Jun; 311(2):354-7. PubMed ID: 8203897
[TBL] [Abstract][Full Text] [Related]
10. Sphingolipid activator protein D (sap-D) stimulates the lysosomal degradation of ceramide in vivo.
Klein A; Henseler M; Klein C; Suzuki K; Harzer K; Sandhoff K
Biochem Biophys Res Commun; 1994 May; 200(3):1440-8. PubMed ID: 8185598
[TBL] [Abstract][Full Text] [Related]
11. The role of ceramide in receptor- and stress-induced apoptosis studied in acidic ceramidase-deficient Farber disease cells.
Burek C; Roth J; Koch HG; Harzer K; Los M; Schulze-Osthoff K
Oncogene; 2001 Oct; 20(45):6493-502. PubMed ID: 11641773
[TBL] [Abstract][Full Text] [Related]
12. Neutral ceramidase gene: role in regulating ceramide-induced apoptosis.
Choi MS; Anderson MA; Zhang Z; Zimonjic DB; Popescu N; Mukherjee AB
Gene; 2003 Oct; 315():113-22. PubMed ID: 14557071
[TBL] [Abstract][Full Text] [Related]
13. Natural ceramide is unable to escape the lysosome, in contrast to a fluorescent analogue.
Chatelut M; Leruth M; Harzer K; Dagan A; Marchesini S; Gatt S; Salvayre R; Courtoy P; Levade T
FEBS Lett; 1998 Apr; 426(1):102-6. PubMed ID: 9598987
[TBL] [Abstract][Full Text] [Related]
14. The in situ degradation of ceramide, a potential lipid mediator, is not completely impaired in Farber disease.
Levade T; Tempesta MC; Salvayre R
FEBS Lett; 1993 Aug; 329(3):306-12. PubMed ID: 8365472
[TBL] [Abstract][Full Text] [Related]
15. Metabolism of ceramide-containing endocytotic vesicles in human diploid fibroblasts.
Sutrina SL; Chen WW
J Biol Chem; 1982 Mar; 257(6):3039-44. PubMed ID: 7061463
[TBL] [Abstract][Full Text] [Related]
16. Ceramide as an activator lipid of cathepsin D.
Heinrich M; Wickel M; Winoto-Morbach S; Schneider-Brachert W; Weber T; Brunner J; Saftig P; Peters C; Krönke M; Schütze S
Adv Exp Med Biol; 2000; 477():305-15. PubMed ID: 10849758
[TBL] [Abstract][Full Text] [Related]
17. Molecular analysis of acid ceramidase deficiency in patients with Farber disease.
Bär J; Linke T; Ferlinz K; Neumann U; Schuchman EH; Sandhoff K
Hum Mutat; 2001 Mar; 17(3):199-209. PubMed ID: 11241842
[TBL] [Abstract][Full Text] [Related]
18. Prosaposin deficiency: further characterization of the sphingolipid activator protein-deficient sibs. Multiple glycolipid elevations (including lactosylceramidosis), partial enzyme deficiencies and ultrastructure of the skin in this generalized sphingolipid storage disease.
Bradová V; Smíd F; Ulrich-Bott B; Roggendorf W; Paton BC; Harzer K
Hum Genet; 1993 Sep; 92(2):143-52. PubMed ID: 8370580
[TBL] [Abstract][Full Text] [Related]
19. Ceramide conversion to sphingosine-1-phosphate is essential for survival in C3H10T1/2 cells.
Castillo SS; Teegarden D
J Nutr; 2001 Nov; 131(11):2826-30. PubMed ID: 11694603
[TBL] [Abstract][Full Text] [Related]
20. Stress-induced apoptosis is not mediated by endolysosomal ceramide.
Ségui B; Bezombes C; Uro-Coste E; Medin JA; Andrieu-Abadie N; Augé N; Brouchet A; Laurent G; Salvayre R; Jaffrézou JP; Levade T
FASEB J; 2000 Jan; 14(1):36-47. PubMed ID: 10627278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
